104 related articles for article (PubMed ID: 2530180)
1. Reconstitution of cytolytic alloreactivity with N-[4-[(4-fluorophenyl) sulfonyl]phenyl]acetamide (CL 259,763) in animals immunocompromised by cyclophosphamide.
Wang BS; Lumanglas AL; James JP; Kelley KA; Silva J; Ruszala-Mallon V; Lin YI; Durr FE
Int J Immunopharmacol; 1989; 11(5):479-86. PubMed ID: 2530180
[TBL] [Abstract][Full Text] [Related]
2. Restoration of cytolytic T-lymphocyte response with a new immunopotentiator, N-(4-[(4-fluorophenyl)sulfonyl]phenyl)acetamide (CL 259, 763), in mice.
Wang BS; Ruszala-Mallon VM; Lumanglas AL; Silva J; Durr FE
Cancer Res; 1988 Apr; 48(8):2135-7. PubMed ID: 3258185
[TBL] [Abstract][Full Text] [Related]
3. In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.
Peppoloni S; Mathieson BJ; Herberman RB; Overton RW; Gorelik E
Cancer Immunol Immunother; 1987; 24(1):49-56. PubMed ID: 2949833
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
5. Generation of tumoricidal effector cells with a novel potentiator: N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide (CL 259,763).
Wang BS; Lumanglas AL; Lin YI; Durr FE
Int J Immunopharmacol; 1990; 12(3):307-14. PubMed ID: 2329020
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the immune response to tumors by a novel synthetic compound, N-[4-[(4-fluorophenyl)sulfonyl]phenyl] acetamide (CL 259,763).
Wang BS; Ruszala-Mallon V; Wallace RE; Citarella RV; Lin YI; Durr FE
Cancer Immunol Immunother; 1986; 22(1):8-14. PubMed ID: 2939949
[TBL] [Abstract][Full Text] [Related]
7. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
8. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
Suzuki R; Suzuki S; Ebina N; Kumagai K
J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
[TBL] [Abstract][Full Text] [Related]
9. The effect of cyclophosphamide on cytotoxic T-lymphocyte responses: inhibition of helper T-cell induction in vitro.
Varkila K; Hurme M
Immunology; 1983 Mar; 48(3):433-8. PubMed ID: 6219062
[TBL] [Abstract][Full Text] [Related]
10. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.
Mayumi H; Good RA
J Exp Med; 1989 Jan; 169(1):213-38. PubMed ID: 2642528
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 2 induces both, growth and maturation of lectin reactive Lyt-2+ but not Lyt-2-precursor cells and regulates the cytolytic potential of effector cells.
Hochgeschwender U; Diamantstein T; Prester M; Nerz G; Simon MM
Immunobiology; 1986 Apr; 171(3):274-301. PubMed ID: 3086217
[TBL] [Abstract][Full Text] [Related]
12. Abrogation of anti-Pichinde virus cytotoxic T cell memory by cyclophosphamide and restoration by coinfection or interleukin 2.
Walker CM; Paetkau V; Rawls WE; Rosenthal KL
J Immunol; 1985 Aug; 135(2):1401-7. PubMed ID: 2989365
[TBL] [Abstract][Full Text] [Related]
13. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
Via CS; Sharrow SO; Shearer GM
J Immunol; 1987 Sep; 139(6):1840-9. PubMed ID: 2957440
[TBL] [Abstract][Full Text] [Related]
14. Regulation of primary cytotoxic T lymphocyte responses generated during mixed leukocyte culture with H-2d identical Qa-1-disparate cells.
Huston DP; Tavana G; Rich RR; Gressens SE
J Immunol; 1986 Sep; 137(6):1776-81. PubMed ID: 2943800
[TBL] [Abstract][Full Text] [Related]
15. Lethal vaccinia infection in cyclophosphamide-suppressed mice is associated with decreased expression of Thy-1, Lyt-2 and L3T4 and diminished IL-2 production in surviving T cells.
Tabi Z; Allan JE; Ceredig R; Doherty PC
Immunology; 1988 Mar; 63(3):423-9. PubMed ID: 2895062
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57Bl/6 mice.
Nikcevich DA; Duffie GP; Young MR; Ellis NK; Kaufman GE; Wepsic HT
Cell Immunol; 1987 Oct; 109(2):349-59. PubMed ID: 2959374
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.
Awwad M; North RJ
Cancer Res; 1989 Apr; 49(7):1649-54. PubMed ID: 2522344
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
Mokyr MB; Colvin M; Dray S
Int J Immunopharmacol; 1985; 7(1):111-22. PubMed ID: 3922904
[TBL] [Abstract][Full Text] [Related]
20. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells.
Maruyama M; Suzuki H; Yamashita N; Yano S
Transplantation; 1990 Aug; 50(2):272-7. PubMed ID: 1696410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
